Business
Portfolio co Istesso phase 2a trials, R&D collab
Portfolio co Istesso phase 2a trials, R&D collab.
About this update from Ip Group Plc
[{"type":"text","content":"\n \nRNS Number : 5936O IP Group PLC 22 August 2017 \n\n\n\n\n\nFOR RELEASE ON\n\n\n22 August 2017\n\n\n\n\n \n \nIP Group plc - Istesso commences Phase 2a for MBS2320 in rheumatoid arthritis and expands R&D collaboration with Janssen\n \nIP Group plc (LSE: IPO) (\"IP Group\" or \"the Group\"), the developer of intellectual property-based businesses, is pleased to note that Istesso Limited (formerly Modern Biosciences plc) has announced the successful dosing of the first patients in a Phase 2a study of its investigational drug, MBS2320, for the treatment of rheumatoid arthritis (\"RA\").\n \nThe progression to Phase 2a follows the successful completion of dosing in a Phase 1 study and is accompanied by an expansion of the financial terms of Istesso's 2014 Option and Licence Agreement with Janssen Biotech, Inc. (\"Janssen\").\n \nMBS2320 is a first-in-class metabolic reprogramming agent for the treatment of RA and is distinguished from existing treatments by its dual mode-of-action that not only reduces inflammation, thereby preventing the progression of disease, but may also promote bone and joint remodelling.\n \nThe progression to Phase 2a follows the analysis of data emerging from a Phase 1 trial in which MBS2320 has demonstrated good safety and tolerability in healthy volunteers, as well as predictable blood exposure levels (\"pharmacokinetics\"). Analysis of the data from a cohort of RA patients included in the trial is ongoing, with good safety and tolerability observed to date.\n \nDr Sam Williams, CEO of Istesso and Head of Biotech at IP Group, said: \"We are pleased to see MBS2320 progress into Phase 2a, representing a significant developmental milestone for this programme. Istesso is focussed on the rapidly emerging field of immunometabolism, with MBS2320 its lead, first-in-class agent. Behind MBS2320, Istesso has a pipeline of assets that work by reprogramming metabolism to treat autoimmune and inflammatory conditions such as multiple sclerosis, psoriasis and ulcerative colitis.\" \n \nThe Phase 2a study is a 12-week randomised, placebo-controlled, double-blind, multi-centre trial assessing the safety, tolerability and efficacy of MBS2320. Istesso anticipates that results will be available in late 2018.\n \nIstesso is a majority-owned ...